Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) EBITDA (2019 - 2025)

Pulmonx (LUNG) has disclosed EBITDA for 7 consecutive years, with -$14.4 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 5.68% to -$14.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$57.0 million, a 0.94% decrease, with the full-year FY2024 number at -$56.9 million, up 4.78% from a year prior.
  • EBITDA was -$14.4 million for Q3 2025 at Pulmonx, up from -$14.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$10.1 million in Q3 2021 to a low of -$16.1 million in Q1 2022.
  • A 5-year average of -$14.1 million and a median of -$14.4 million in 2025 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 164.33% in 2021, then grew 8.91% in 2024.
  • Pulmonx's EBITDA stood at -$12.8 million in 2021, then fell by 9.87% to -$14.1 million in 2022, then increased by 6.47% to -$13.2 million in 2023, then fell by 3.06% to -$13.6 million in 2024, then decreased by 5.58% to -$14.4 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBITDA are -$14.4 million (Q3 2025), -$14.7 million (Q2 2025), and -$14.4 million (Q1 2025).